Lead Product(s) : Febuxostat
Therapeutic Area : Rheumatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Laboratories Announces the Launch of Febuxostat Tablets in the U.S. Market
Details : Febuxostat Tablets, is a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets. Dr. Reddy’s Febuxostat Tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets.
Product Name : Febuxostat-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2021
Lead Product(s) : Febuxostat
Therapeutic Area : Rheumatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Febuxostat
Therapeutic Area : Rheumatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Final Approval from The USFDA for Febuxostat Tablets
Details : Febuxostat is a xanthine oxidase inhibitor, indicated to lower hyperuricemia (high uric acid in the blood) in patients with gout who have been treated with allopurinol that did not work well or cannot be treated with allopurinol.
Product Name : Zurig
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 01, 2023
Lead Product(s) : Febuxostat
Therapeutic Area : Rheumatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
